Home > Insider Trading > Filing (0001209191-21-002246)

Filing Details

Accession Number:: 0001209191-21-002246
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-06 17:26:26
Reporting Period:: 2021-01-04

Accepted Time:: 2021-01-06 17:26:26
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1623526	Stoke Therapeutics Inc.	STOK	Pharmaceutical Preparations (2834)	471144582

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1780085	M. Huw Nash	C/O Stoke Therapeutics, Inc. 45 Wiggins Avenue Bedford MA 01730	Coo & Cbo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-01-04	5,700	$2.19	5,732	No	4	M	Direct
Common Stock	Disposition	2021-01-04	1,500	$57.66	4,232	No	4	S	Direct
Common Stock	Disposition	2021-01-04	2,200	$59.02	2,032	No	4	S	Direct
Common Stock	Disposition	2021-01-04	1,800	$59.85	232	No	4	S	Direct
Common Stock	Disposition	2021-01-04	200	$60.51	32	No	4	S	Direct
Common Stock	Disposition	2021-01-06	32	$57.14	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2021-01-04	5,700	$0.00	5,700	$2.19

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
125,397		2018-12-12	No	4	M	Direct

Footnotes

Includes 32 shares of Common Stock acquired under the issuer's employee stock purchase plan on December 31, 2020.
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.33 to $58.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.395 to $59.355 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.395 to $60.33 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.50 to $60.515 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.